RILPIVIRINE , JNJ-16150108
Phase 2 small_molecule active
Quick answer
RILPIVIRINE , JNJ-16150108 for HIV-1 Infection is a Phase 2 program (small_molecule) at Janssen Pharmaceutica N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Pharmaceutica N.V.
- Indication
- HIV-1 Infection
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active